This Program for a Common Problem May Be Vertex Pharmaceuticals' Ticket to a New Wave of Billion-Dollar Revenues
Vertex Pharmaceuticals (NASDAQ: VRTX) generates billions of dollars in annual revenues from its treatments for the rare disease cystic fibrosis. And Vertex should continue to dominate in cystic fibrosis and bring in blockbuster revenue well into the future thanks to its life-saving treatments. But the big biotech company may soon also make headlines with a treatment for a far more common problem -- and this could result in a whole new massive revenue stream.
We've all suffered from this problem at one time or another. I'm talking about pain. The problem is that treatment options today are limited to a few over-the-counter options or prescription opioids. Vertex's candidate, VX-548, is a non-opioid option that the company thinks could take the market by storm.
Image source: Getty Images.
Source Fool.com
Vertex Pharmaceuticals Inc. Stock
The stock is one of the favorites of our community with 71 Buy predictions and 2 Sell predictions.
With a target price of 515 € there is a slightly positive potential of 14.84% for Vertex Pharmaceuticals Inc. compared to the current price of 448.45 €.
